濮阳东方妇科医院做人流咨询电话濮阳东方男科医院值得选择,濮阳东方医院妇科做人流手术值得信赖,濮阳东方男科医院口碑评价高,濮阳东方几点上班,濮阳东方妇科医院做人流价格合理,濮阳东方医院看妇科非常好,濮阳东方医院男科看早泄价格不贵

SAN FRANCISCO, Dec. 9 (Xinhua) -- Apple on Friday suffered a major setback in its global patent war, as a German court ruled over its copyright infringement battle in favor of Motorola Mobility.The German court ruled that Apple's iPhone and iPad infringe a Motorola patent and issued an injunction banning the import of iPhones and 3G-capable iPads into Germany.The dispute, one of Apple's several patent lawsuits around the world, is over a Motorola patent essential to GPRS. Motorola has been negotiating with Apple over licensing terms and conditions since 2007, and it will continue its efforts to resolve its global patent dispute as soon as practicable, said Motorola Mobility in a statement on Friday."We're going to appeal the court's ruling right away. Holiday shoppers in Germany should have no problem finding the iPad or iPhone they want," an Apple spokesman told tech news site AllThingsD.Apple is not too concerned about losing out in the Christmas shopping season as it has plenty of iPhones and iPads in Germany already, AllThingsD cited unidentified sources as saying.The ruling is against Apple's European sales company and only impacts its products sold in Germany. The German court also ruled that Motorola is entitled to a damages award.Apple can appeal the ruling to a higher court and request a stay of the injunction, according to a blog post of Florian Mueller, a U.S. patent expert who has been closely following patent lawsuits in the mobile industry.Mueller said should Apple make the appeal but the court declines the stay, Motorola must post a 100 million euro (around 134 million U.S. dollars) bond before the court will enforce the injunction.In August, Apple also filed a suit in Germany over the design of Motorola's tablet Xoom, which runs Google's Android system. But Apple did not make it clear whether it will seek to block the sales of Xoom in Europe.Also on Friday, Samsung won an appeal from the Australian High Court overturning a previous Apple victory that effectively banned Samsung from selling its Galaxy Tab in Australia.Based on claims of infringing Apple's patents, the Cupertino, California-based tech giant has been seeking court order to block Samsung's Galaxy line of mobile devices around the world.A German court issued an injunction in August, blocking Samsung from selling its Galaxy Tab 10.1 tablets across all European Union members, except for the Netherlands.On Thursday, Apple said it will appeal a San Jose, California judge's refusal to ban sales of Samsung 4G smartphones and Galaxy Tab 10.1 tablets in the United States.

BEIJING, Oct. 27 (Xinhuanet) -- A new study shows that it's not simply a lack of willpower that explains weight regain but hormones keep one insisting on eating, a persistent biological urge. As any dieter knows, it's hard to keep weight off. Weight regain is a familiar problem for dieters. The research appears in Thursday's issue of the New England Journal of Medicine. To study what drives it, Proietto and his colleagues enrolled 50 overweight or obese patients in Australia in a 10-week diet program. On average, the participants lost almost 30 pounds in the 10 weeks - faster than the standard advice of losing a pound or two per week. Even so, they gained an average of 12 pounds back over the next year. The scientists checked the blood levels of nine hormones known to influence appetite - and found that even a year after the end of the weight-loss program, six of the hormones were still out of whack. People who regain weight should not be harsh on themselves, as eating is our most basic instinct, study author Joseph Proietto of the University of Melbourne in Australia said. It's better not to gain weight than to try to lose it.

SAN FRANCISCO, Oct. 5 (Xinhua) -- Google announced Wednesday that Google Earth, the tech giant's virtual globe, map and geographical information program, has been downloaded more than one billion times since it was first introduced in 2005.According to Google's official blog, there have been more than one billion downloads of the Google Earth desktop client, mobile apps and the Google Earth plug-in. To celebrate the milestone, Google is aggregating all the interesting ways people have used Google Earth around the world and posting them on "www. OneWorldManyStories.com.""We never imagined our geospatial technology would be used by people in so many unexpected ways," said Google in the blog post.Google Earth maps the Earth by images obtained from satellite imagery, aerial photography and GIS (geographic information system) 3D globe. It also has versions of Moon, Mars and Sky, enabling users to see images and videos of the planets and distant galaxies.It is currently available in Google Earth, a free version with limited function, as well as Google Earth Pro and Google Earth Enterprise, subscription services with additional features intended for commercial use.

BEIJING, Nov. 7 (Xinhuanet) -- A huge asteroid will pass closer to Earth than the moon on Tuesday, but experts say there is no cause for alarm.Asteroid 2005 YU 55 will pass about 300-thousand kilometers from the earth. The giant space rock is about 400 meters in diameter. The close encounter will occur at 23:28 Greenwich Mean Time. Computer models showing the asteroid’s path for the next 100 years show there is no chance it will hit Earth during that time.Previous studies show the asteroid is what is called a C-type asteroid that is likely made of carbon-based materials and some silicate rock.

WASHINGTON, Dec. 21 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Wednesday approved Isentress for the treatment of HIV-1 infection for children and adolescents.The drug is part of a class of medications called HIV integrase strand transfer inhibitors that works by slowing the spread of HIV in the body. It was first approved for use in adult patients in October 2007, under FDA's accelerated approval program."Many young children and adolescents are living with HIV and this approval provides an important additional option for their treatment," said Edward Cox, director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research.Isentress is a pill that can be taken twice daily, with or without food. The pill is also available in a chewable form. As the two tablet formulations are not interchangeable, the chewable form is only approved for use in children ages 2 to 11.A single, multi-center clinical trial of 96 children and adolescents aged 2-18 years with HIV-1 infection evaluated the safety and effectiveness of Isentress. These patients previously received treatment for HIV-1 infection. After 24 weeks of treatment with Isentress, 53 percent of these patients had an undetectable amount of HIV in their blood.According to the FDA, the most commonly reported severe, treatment-related side effects in patients taking Isentress include trouble sleeping and headache. The frequency of these side effects is similar for children and adults. One pediatric patient reported severe treatment-related insomnia, while another pediatric patient experienced a drug-related skin rash.